lung cancer Archives
AI used to identify patients at risk for lung cancer
Dec. 16, 2021— by Matt Batcheldor The Vanderbilt Lung Institute is the first location in Tennessee to debut Optellum Virtual Lung Nodule Clinic comprehensive management software that, using artificial intelligence, can identify and track patients at risk for lung cancer — even if they have never been in for a cancer screening. That’s because the Optellum software...
Clinical trial tests ATR inhibitor in difficult-to-treat cancers
Sep. 23, 2021— by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...
Facebook campaign quickly nets clinical trial participants
Aug. 5, 2021—The cost and effectiveness of social media as a participant recruitment tool for clinical research is still being evaluated. To better understand its utility, researchers at Vanderbilt University Medical Center used Facebook to mount a short, monthlong pilot campaign in and around Houston attempting to recruit participants for an ongoing smoking cessation study being conducted in that city.
Study shows benefit of scheduling lung screens with mammograms
Jun. 23, 2021—Women who are longtime smokers could potentially save their lives by undergoing lung screens on the same day they schedule mammograms, according to a study by Vanderbilt researchers published in the Journal of Medical Screening.
Effort seeks to enroll more Black patients in lung cancer trials
Mar. 25, 2021—Researchers from Vanderbilt University Medical Center are part of a multi-institutional study that aims to improve participation in lung cancer clinical trials among Black patients from Southern states.
Vanderbilt research played key role in new lung screen guidelines
Mar. 18, 2021—The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
EGFR Resisters/LUNGevity fund lung cancer research
Mar. 18, 2021—Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.
Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening
Mar. 9, 2021—A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.
Gift in memory of Phran Galante boosts lung cancer research
Feb. 25, 2021—A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.
New therapeutic target for lung cancer
Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
Newer targeted therapy prolongs life for lung cancer patients
Aug. 13, 2020—Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.
Iams honored by National Comprehensive Cancer Network
Jul. 30, 2020—Wade Iams, MD, MSCI, assistant professor of Medicine, is the recipient of a National Comprehensive Cancer Network Foundation Young Investigator Award.
